Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF -Mutant Melanoma

PURPOSE: BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti-PD-1/anti-CTLA-4) have transformed the treatment of BRAF-mutant metastatic melanoma. While most patients who respond to targeted therapy eventually progress, a subset derives durable benefit, and biomarkers to identify this subset would inform optimal treatment selection. EXPERIMENTAL DESIGN: We analyzed pre-treatment tumor samples from a clinically annotated cohort of 155 patients with BRAF-mutant metastatic melanoma treated with first-line BRAFi/MEKi and followed for up to five years. Whole-exome sequencing (WES) was performed to derive genomic features, and spatial immunohistochemistry (IHC) characterized the tumor immune microenvironment in a subset of samples. Patients were classified as durable responders (PFS ≥ 24 months) and rapid progressors (PFS < 6 months with progression). RESULTS: A global metric of tumor genomic heterogeneity, rather than individual gene alterations, distinguished these groups. Combining genomic heterogeneity with baseline tumor burden (e.g., lactate dehydrogenase (LDH) or radiographic lesion dimensions), we developed a parsimonious model that predicted durable responders with high precision and specificity. Notably, the analogous population of patients treated instead with immunotherapy were not durable responders, suggesting that the selected predictors of durable responders are targeted therapy specific. Spatial profiling of the immune microenvironment in a subset of pre-treatment biopsies (n = 47) demonstrated that high intratumoral, but not peritumoral, CD8+ T-cell infiltration predicted prolonged survival on BRAF-targeted therapy. CONCLUSION/DISCUSSION: These findings highlight the distinct baseline intrinsic and extrinsic features underlying durable response to BRAF-targeted therapy and support their potential implication in guiding treatment selection for patients with BRAF-mutant metastatic melanoma.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1158/1078-0432.ccr-26-2232
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF -Mutant Melanoma

Alexander Savchenko, Jan C. Brase, Keith T. Flaherty, Amy Y. Huang et al.
1 links
Clinical Cancer Research
Melanoma and MAPK Pathways
article

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF -Mutant Melanoma

Alexander Savchenko, Jan C. Brase, Keith T. Flaherty, Amy Y. Huang, Eliezer M. Van Allen, Levi A. Garraway, Cora A. Ricker, Michael P. Manos, Giuseppe Tarantino, Brendan Michael Reardon, J Park, David Liu, Yingxiao Shi
article en

Abstract

PURPOSE: BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti-PD-1/anti-CTLA-4) have transformed the treatment of BRAF-mutant metastatic melanoma. While most patients who respond to targeted therapy eventually progress, a subset derives durable benefit, and biomarkers to identify this subset would inform optimal treatment selection. EXPERIMENTAL DESIGN: We analyzed pre-treatment tumor samples from a clinically annotated cohort of 155 patients with BRAF-mutant metastatic melanoma treated with first-line BRAFi/MEKi and followed for up to five years. Whole-exome sequencing (WES) was performed to derive genomic features, and spatial immunohistochemistry (IHC) characterized the tumor immune microenvironment in a subset of samples. Patients were classified as durable responders (PFS ≥ 24 months) and rapid progressors (PFS < 6 months with progression). RESULTS: A global metric of tumor genomic heterogeneity, rather than individual gene alterations, distinguished these groups. Combining genomic heterogeneity with baseline tumor burden (e.g., lactate dehydrogenase (LDH) or radiographic lesion dimensions), we developed a parsimonious model that predicted durable responders with high precision and specificity. Notably, the analogous population of patients treated instead with immunotherapy were not durable responders, suggesting that the selected predictors of durable responders are targeted therapy specific. Spatial profiling of the immune microenvironment in a subset of pre-treatment biopsies (n = 47) demonstrated that high intratumoral, but not peritumoral, CD8+ T-cell infiltration predicted prolonged survival on BRAF-targeted therapy. CONCLUSION/DISCUSSION: These findings highlight the distinct baseline intrinsic and extrinsic features underlying durable response to BRAF-targeted therapy and support their potential implication in guiding treatment selection for patients with BRAF-mutant metastatic melanoma.

Clinical Cancer Research
Novartis (Switzerland) (CH), Genentech (US), Massachusetts General Hospital (US), Acentech (United States) (US), Dana-Farber Cancer Institute (US), Novartis (United States) (US), Center for Cancer Research (US), Novartis Foundation (CH)
National Institutes of Health, National Cancer Institute
Good health and well-being
Melanoma and MAPK Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon